Evolving Role of Biomarkers in Prostate Cancer : Episode 8
Opinion
Video
Influences and Challenges of Biomarkers on Treatment Selection
The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.
Video Player is loading.
Video content above is prompted by the following question:
- Please discuss different treatment approaches (e.g. surgery, radiation, hormone therapy) and how biomarkers may have influenced your choice.
- What criteria do you use to decide between treatment options based on biomarker testing results?
- What challenges and/or barriers have you encountered when selecting a biomarker?
- Is there one that you use for a specific patient population?
Related Videos
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Jason Hafron, MD, predicts coming advancements in bladder cancer
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Dr Louise Kostos discusses combination therapies in mHSPC
Related Content
